ClinicalTrials.gg
RecruitingNCT06471166Updated Jun 24, 2024

The Effect of Different Treatment Modalities of Tubal Ectopic Pregnancy on Ovarian Reserve: a Prospective Cohort Study

An observational study in Ectopic Pregnancy, sponsored by Assiut University. Recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 44 Years. Per ClinicalTrials.gov, last updated 2024-06-24.

Sponsored by Assiut University · Observational

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
90
Ages
18 Years to 44 Years
Sex
Female
01

Study summary

Detect the effect of different treatment modalities of tubal ectopic pregnancy on ovarian reserve

02

Conditions studied

  • Ectopic Pregnancy

Browse trials for

03

In context

Pregnancy, Ectopic

83 studies on the registry are indexed under Pregnancy, Ectopic; 21 are open to participants now.

This study's planned enrollment of 90 is below the median of 150 across 39 observational studies indexed under Pregnancy, Ectopic.

Browse Pregnancy, Ectopic studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
Female
Sampling method
Probability sample

Study population

Women's Health Hospital, Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The study will include patients aged 18-44 years with known diagnosis or suspicion of diagnosis of tubal ectopic pregnancy (abnormal doubling rates of their b-HCG levels as well as ultrasonographically identified or unidentified gestational sacs outside the uterus)
  • Included patients must have capacity to provide . Given the potential emergent nature of presentation, women will not be recruited if fully informed consent could be compromised due to a highly distressed emotional state or significant hemorrhage necessitating the need for urgent surgery

Exclusion criteria

Exclusion Criteria:

  1. The use of hormonal within two months of enrolment
  2. If other surgery was conducted at the time of salpingectomy.
  3. If a woman was pregnant at follow up visit for AMH measurement
  4. History of previous surgeries of fallopian tubes and/or ovaries
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • Conservative management

    Diagnostic Test: Amh hormone

  • Medical treatment

    Diagnostic Test: Amh hormone

  • Surgical treatment (Open or laparoscopic salpingectomy)

    Diagnostic Test: Amh hormone

  • Surgical treatment after failed medical treatment (Open or laparoscopic salpingectomy)

    Diagnostic Test: Amh hormone

  • Conservative surgical treatment (salpingotomy, salpingostomy, tubal milking)

    Diagnostic Test: Amh hormone

  • Conservative surgical treatment after failed medical treatment

    Diagnostic Test: Amh hormone

Interventions

  • Diagnostic testAmh hormone

    Ovarian reserve

06

What researchers measure

Primary outcomes

  1. Change in levels of AMH pre and post treatment

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06471166
Lead sponsor
Assiut University
Responsible party
Andro Bahgat Heshmat (Resident, Assiut University) — Principal investigator
First posted
Jun 24, 2024
Start date
Jul 10, 2024 (estimated)
Primary completion
Oct 1, 2025 (estimated)
Completion
Oct 10, 2025 (estimated)
Last update
Jun 24, 2024

Study contacts

Andro Bahgat, MD
Contact
androbahgat7@gmail.com
01283104773
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion